Discovery Biology

Discovery Biology Unit provides validated discovery assays, including in vitro assays (HTS, SAR screening support, compound selectivity and early safety profiling, and cancer cell panel profiling) and in vivo disease models in cardiovascular, CNS, respiratory, metabolic and infectious diseases. Founded in 2008, we have multiple function teams of ~500 scientists, including 11% PhD, 55% MSc, and led by 12 seasoned scientific leaders with an average of 15 years of R&D experience in the US, Canada, and UK.

Structural Biology

WuXi Biology offers structural biology services with customized and integrated solutions to advance your discovery projects

in vitro Biology

WuXi Biology offers comprehensive assays services that cover all major therapeutic target classes to support the in vitro pharmacological characterization.  Our in vitro biology services include HTS, SAR screening support, compound selectivity and early safety profiling, and cancer cell panel profiling.

in vivo Pharmacology

WuXi Biology has established multiple in vivo animal models to evaluate preclinical drug candidates.  Each disease model is designed to understand specific aspects of drug property and its mechanism of action. 

Infectious Disease Unit

WuXi Biology provides a comprehensive infectious disease platform from assay setup to clinical trial support.

Oncology and Immuno-oncology Unit

Our innovative platform covers all research needs ranging from target discovery, in vitro and in vivo pharmacology, and translational research to clinical biomarker testing enabling drug discovery for cancer, autoimmune disease and rare genetic diseases (RGD).

Fully integrated hit finding campaigns with medicinal chemistry, in vitro biology and ADME for lead optimization Highthroughput Screening HTS Affinity Selection Mass Spectrometry (ASMS) Screening DNA-Encoded Library (DEL) Fragment-based Drug Discovery Virtual Screening (CADD)

Immunology End-to-end services and solutions to enable cancer drug discovery Discovery and clinical biomarker services by pathology and flow-cytometry in cells or mice, fromconcept to disease models and efficacy studies A large collection andtumors model for small& large molecule drugdrug discovery Tumor Models Target Validation Biomarker